Jeffrey A. Toretsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey A. Toretsky has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Aykut Üren
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
32 shared publications - Purushottam Babu Tiwari
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
31 shared publications - Emre Deniz
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
30 shared publications - Anna Molotkova
Georgetown University Medical Center 1 Lombardi Comprehensive Cancer Center Washington, District of Columbia
28 shared publications - Adam Shlien
Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
27 shared publications - Eric Glasgow
Department of Oncology, Georgetown University Medical Center, Washington, USA
26 shared publications
Latest Publications
- Open Access
PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells
Background/Objectives: Fusion-positive rhabdomyosarcoma (FP-RMS) is characterized by the presence of tumor-specific chromosomal translocation products, most commonly PAX3::FOXO1, and typically results in lower survival rates compared to fusion-negative RMS cases. PAX3::FOXO1 plays a critical role in FP-RMS oncogenesis in both tumor initiation and maintenance, making it an excellent target for therapeutic intervention in FP-RMS. Methods: We created Proteolysis Targeting Chimeras (PROTACs) by combining PAX3::FOXO1-binding small molecules with E3 ligase recruiters for cereblon (CRBN) or S-Phase Kinase Associated Protein 1 (SKP1). Results: The PROTACs achieved up to 70% degradation of the endogenous PAX3::FOXO1 protein in FP-RMS cell lines in a concentration-, time-, and proteasome-dependent manner. Moreover, the PROTAC-mediated targeted degradation of PAX3::FOXO1 in FP-RMS cells deregulated the endogenous PAX3::FOXO1 gene expression signature and induced myogenic differentiation. Importantly, treatment of FP-RMS cells with PAX3::FOXO1-PROTACs synergized with vincristine treatment and impaired >80% of anchorage-independent growth in soft agar. Conclusions: Taken together, we demonstrate the proof of principle of PROTACs targeting the oncogenic fusion protein PAX3::FOXO1 in FP-RMS cells. The PROTACs created in this study will not only be useful tools in studying PAX3::FOXO1 biology in laboratory models but could also serve as molecular scaffolds for designing clinical-grade molecules to assess the therapeutic potential of PAX3::FOXO1-targeting PROTACs in FP-RMS patients.
Open AccessPAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells
Background/Objectives: Fusion-positive rhabdomyosarcoma (FP-RMS) is characterized by the presence of tumor-specific chromosomal translocation products, most commonly PAX3::FOXO1, and typically results in lower survival rates compared to fusion-negative RMS cases. PAX3::FOXO1 plays a critical role in FP-RMS oncogenesis in both tumor initiation and maintenance, making it an excellent target for therapeutic intervention in FP-RMS. Methods: We created Proteolysis Targeting Chimeras (PROTACs) by combining PAX3::FOXO1-binding small molecules with E3 ligase recruiters for cereblon (CRBN) or S-Phase Kinase Associated Protein 1 (SKP1). Results: The PROTACs achieved up to 70% degradation of the endogenous PAX3::FOXO1 protein in FP-RMS cell lines in a concentration-, time-, and proteasome-dependent manner. Moreover, the PROTAC-mediated targeted degradation of PAX3::FOXO1 in FP-RMS cells deregulated the endogenous PAX3::FOXO1 gene expression signature and induced myogenic differentiation. Importantly, treatment of FP-RMS cells with PAX3::FOXO1-PROTACs synergized with vincristine treatment and impaired >80% of anchorage-independent growth in soft agar. Conclusions: Taken together, we demonstrate the proof of principle of PROTACs targeting the oncogenic fusion protein PAX3::FOXO1 in FP-RMS cells. The PROTACs created in this study will not only be useful tools in studying PAX3::FOXO1 biology in laboratory models but could also serve as molecular scaffolds for designing clinical-grade molecules to assess the therapeutic potential of PAX3::FOXO1-targeting PROTACs in FP-RMS patients.
- 17 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (929) , eady8367
The unphosphorylated, closed form of ezrin binds to RNA to maintain a metastatic phenotype in osteosarcoma cells
Ezrin is a cytoplasmic protein that can exist in multiple conformations that are regulated by phosphorylation at Thr 567 . The phosphorylated, open form of ezrin generally has been considered the active form because it translocates to the plasma membrane. In contrast, the unphosphorylated, closed form of ezrin is sequestered in the cytoplasm and is considered inactive, although it directly interacts with cytoplasmic RNA binding proteins. Here, we found that the closed form of ezrin is itself an RNA binding protein with biological activity. The abundance of ezrin correlated with that of RBPs in human osteosarcoma samples. Purified recombinant ezrin protein engineered to maintain a closed conformation (rEZRIN-T567A) directly bound RNA, with greatest affinity for guanine-rich sequences and RNA G-quadruplexes (G4 RNAs). Expressing closed ezrin in ezrin-null osteosarcoma cells restored the transcriptomic and proteomic profiles. Closed ezrin bound to endogenous mRNAs associated with pathways related to RNA processing and splicing, DNA maintenance, and cellular metabolism. In zebrafish, expression of closed ezrin rescued the metastatic capability of ezrin-null osteosarcoma xenografts. Our findings demonstrate that the closed conformation of ezrin—previously thought to be inactive—can directly bind RNA, regulate transcription and translation, and contribute to a metastatic phenotype in osteosarcoma cells.
- 17 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (929) , eady8367
The unphosphorylated, closed form of ezrin binds to RNA to maintain a metastatic phenotype in osteosarcoma cells
Ezrin is a cytoplasmic protein that can exist in multiple conformations that are regulated by phosphorylation at Thr 567 . The phosphorylated, open form of ezrin generally has been considered the active form because it translocates to the plasma membrane. In contrast, the unphosphorylated, closed form of ezrin is sequestered in the cytoplasm and is considered inactive, although it directly interacts with cytoplasmic RNA binding proteins. Here, we found that the closed form of ezrin is itself an RNA binding protein with biological activity. The abundance of ezrin correlated with that of RBPs in human osteosarcoma samples. Purified recombinant ezrin protein engineered to maintain a closed conformation (rEZRIN-T567A) directly bound RNA, with greatest affinity for guanine-rich sequences and RNA G-quadruplexes (G4 RNAs). Expressing closed ezrin in ezrin-null osteosarcoma cells restored the transcriptomic and proteomic profiles. Closed ezrin bound to endogenous mRNAs associated with pathways related to RNA processing and splicing, DNA maintenance, and cellular metabolism. In zebrafish, expression of closed ezrin rescued the metastatic capability of ezrin-null osteosarcoma xenografts. Our findings demonstrate that the closed conformation of ezrin—previously thought to be inactive—can directly bind RNA, regulate transcription and translation, and contribute to a metastatic phenotype in osteosarcoma cells.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 7 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Modulation of ROME expression affects many different pathways in human cancer cells.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 7 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Modulation of ROME expression affects many different pathways in human cancer cells.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Rome knockdown significantly affects calcium signaling and developmental pathways in zebrafish embryos. A, Uniform Manifold Approximation and Projection (UMAP) of 49 annotated clusters from single cells isolated from control MO–injected zebrafish embryos and rome MO–injected zebrafish embryos at 48 hpf. B, Volcano plot showing differentially expressed genes upon rome knockdown by morpholino across all cell populations (pseudobulk). FC, fold change. C and D, Significantly enriched pathways among upregulated genes (C) and downregulated genes (D) from pseudo-bulk differential expression analysis (top 20 pathways, adjusted P value < 0.05). GO, gene ontology. E–H, Violin plots showing significantly increased icn (E), s100t (F), rspo1 (G), and ctslb (H) expression in zebrafish embryos injected with the rome MO compared with that in embryos injected with the control MO. All comparisons shown have an adjusted P value < 0.05 and an average log2 fold change > 0.66 or < −0.66 (denoted by an asterisk: *). I, Treatment with Wnt pathway inhibitor, ICG-001, rescued developmental defects in zebrafish embryos with rome knockdown at 24 hpf and 48 hpf (DMSO group: n = 43; ICG-001 treatment group: n = 41). Statistical significance was calculated via the Fisher exact test (two-sided).
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Rome knockdown significantly affects calcium signaling and developmental pathways in zebrafish embryos. A, Uniform Manifold Approximation and Projection (UMAP) of 49 annotated clusters from single cells isolated from control MO–injected zebrafish embryos and rome MO–injected zebrafish embryos at 48 hpf. B, Volcano plot showing differentially expressed genes upon rome knockdown by morpholino across all cell populations (pseudobulk). FC, fold change. C and D, Significantly enriched pathways among upregulated genes (C) and downregulated genes (D) from pseudo-bulk differential expression analysis (top 20 pathways, adjusted P value < 0.05). GO, gene ontology. E–H, Violin plots showing significantly increased icn (E), s100t (F), rspo1 (G), and ctslb (H) expression in zebrafish embryos injected with the rome MO compared with that in embryos injected with the control MO. All comparisons shown have an adjusted P value < 0.05 and an average log2 fold change > 0.66 or < −0.66 (denoted by an asterisk: *). I, Treatment with Wnt pathway inhibitor, ICG-001, rescued developmental defects in zebrafish embryos with rome knockdown at 24 hpf and 48 hpf (DMSO group: n = 43; ICG-001 treatment group: n = 41). Statistical significance was calculated via the Fisher exact test (two-sided).
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a 153–amino acid transmembrane glycoprotein. A, Western blots of TC-71 lysates transfected with EV or ROME-HA for 24 hours blotted with the commercially available anti-HA antibody, ICD-6 (monoclonal antibody against the predicted ICD of ROME), and ECD-5 (monoclonal antibody against the predicted ECD of ROME) are shown. B, ROME was knocked out via CRISPR/Cas9 in TC-71 cells. Successful knockout was confirmed by immunoprecipitation and Western blotting with a ROME monoclonal antibody (ICD-6). C, Coomassie blue staining was used to verify the purity of recombinant ROME-FL and ECD proteins and the synthetic ICD peptide. Western blotting with ROME ICD-6 and ECD-5 monoclonal antibodies was performed to confirm protein identities. D, SPR sensorgrams demonstrating the binding of the anti-ROME monoclonal antibody ICD-6 to the ROME ICD and FL proteins and the binding of the anti-ROME monoclonal antibody ECD-5 to the ROME ECD and FL proteins. The antibodies were injected in duplicate at 200, 100, 50, 25, 12.5, and 6.25 nmol/L. The red lines are the actual data and the black lines indicate the curve fit. E, Three-dimensional structure of ROME predicted by AlphaFold. F, A diagram of the ROME amino acid sequence with three predicted domains is shown. Circles correspond to phosphorylation sites and triangles correspond to glycosylation sites. The black color designates sites predicted in silico and the blue color designates sites confirmed by MS. G, Homology between human, mouse, and zebrafish ROME proteins is shown. The Drosophila inaF motif (from the INAF-D protein) is shown for comparison. The black line box indicates the transmembrane domain. Asterisks (*) indicate identical amino acids (aa) and colons (:) indicate amino acids with similarity among all three species. H, Phylogenetic tree showing the high evolutionary conservation of the ROME protein in vertebrates. I, Compared with the eGFP control, ROME-GFP localizes to the plasma membrane of TC-71 cells (quantification shown in the graph to the right). J, ROME-HA was expressed in TC-71 cells and detected primarily in the membrane fraction, as well as the soluble nuclear fraction. α-Tubulin was used as a cytoplasmic fraction control, CD99 was used as a membrane fraction control, and lamin A/C was used as a soluble nuclear fraction control. K, Lysates from TC-71 cells transfected with EV or ROME-FLAG were treated with a deglycosylase mixture. Western blotting with anti-FLAG antibody was performed to detect ROME-FLAG.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a 153–amino acid transmembrane glycoprotein. A, Western blots of TC-71 lysates transfected with EV or ROME-HA for 24 hours blotted with the commercially available anti-HA antibody, ICD-6 (monoclonal antibody against the predicted ICD of ROME), and ECD-5 (monoclonal antibody against the predicted ECD of ROME) are shown. B, ROME was knocked out via CRISPR/Cas9 in TC-71 cells. Successful knockout was confirmed by immunoprecipitation and Western blotting with a ROME monoclonal antibody (ICD-6). C, Coomassie blue staining was used to verify the purity of recombinant ROME-FL and ECD proteins and the synthetic ICD peptide. Western blotting with ROME ICD-6 and ECD-5 monoclonal antibodies was performed to confirm protein identities. D, SPR sensorgrams demonstrating the binding of the anti-ROME monoclonal antibody ICD-6 to the ROME ICD and FL proteins and the binding of the anti-ROME monoclonal antibody ECD-5 to the ROME ECD and FL proteins. The antibodies were injected in duplicate at 200, 100, 50, 25, 12.5, and 6.25 nmol/L. The red lines are the actual data and the black lines indicate the curve fit. E, Three-dimensional structure of ROME predicted by AlphaFold. F, A diagram of the ROME amino acid sequence with three predicted domains is shown. Circles correspond to phosphorylation sites and triangles correspond to glycosylation sites. The black color designates sites predicted in silico and the blue color designates sites confirmed by MS. G, Homology between human, mouse, and zebrafish ROME proteins is shown. The Drosophila inaF motif (from the INAF-D protein) is shown for comparison. The black line box indicates the transmembrane domain. Asterisks (*) indicate identical amino acids (aa) and colons (:) indicate amino acids with similarity among all three species. H, Phylogenetic tree showing the high evolutionary conservation of the ROME protein in vertebrates. I, Compared with the eGFP control, ROME-GFP localizes to the plasma membrane of TC-71 cells (quantification shown in the graph to the right). J, ROME-HA was expressed in TC-71 cells and detected primarily in the membrane fraction, as well as the soluble nuclear fraction. α-Tubulin was used as a cytoplasmic fraction control, CD99 was used as a membrane fraction control, and lamin A/C was used as a soluble nuclear fraction control. K, Lysates from TC-71 cells transfected with EV or ROME-FLAG were treated with a deglycosylase mixture. Western blotting with anti-FLAG antibody was performed to detect ROME-FLAG.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
CRISPR/Cas9 library sequencing primers.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
CRISPR/Cas9 library sequencing primers.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
List of gRNAs identified in CRISPR/Cas9 transcriptional activation screen
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
List of gRNAs identified in CRISPR/Cas9 transcriptional activation screen
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a highly conserved, phosphorylated transmembrane protein that is also present in the nucleus.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a highly conserved, phosphorylated transmembrane protein that is also present in the nucleus.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 8 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME expression drives metastasis development in vivo. A, Timeline of tail vein metastasis experiments. B, In a tail vein metastasis model, mice injected with ROME-overexpressing TC-71 cells (n = 11) had a higher total mass of metastatic nodules than did controls (n = 10). C, In a tail vein metastasis model, mice injected with ROME-KO TC-71 cells (n = 11) had a lower total mass of metastases than controls injected with WT TC71 cells (n = 11). Statistical significance was determined via an unpaired t test (one-tailed) for B and C. D, Diagram of the orthotopic Ewing sarcoma leg amputation experimental timeline. E, Representative gross images of lungs from mice injected with TC-71 cells overexpressing ROME or with EV (left) with quantification (middle). Representative images of H&E staining are shown on the right confirming metastatic nodules in the lungs of SCID mice. Statistical significance was calculated by the Fisher exact test (one-sided). F, TC-71 ROME-KO cells displayed significantly reduced primary tumor recurrence [n = 10 per group, log-rank (Mantel–Cox) test]. G, ROME is expressed throughout many different tumor types (CNS, central nervous system; HEPAC, hepatocellular carcinoma and cholangioma; KICH, kidney chromophobe and other renal carcinoma; KIPCC, papillary cell renal carcinoma; OV, ovarian cystadenocarcinoma; PAAD, pancreatic ductal adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; SCC/BLCA, squamous cell or bladder carcinoma; TGCT SEM, testicular germ cell tumor, seminoma). H, Kaplan–Meier curves of patient survival stratified by high (red line) and low (black line) ROME expression (from the Kaplan–Meier plotter database). [A and D, Created in BioRender. Lab, S. (2026) https://BioRender.com/atgnfw0.]
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 8 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME expression drives metastasis development in vivo. A, Timeline of tail vein metastasis experiments. B, In a tail vein metastasis model, mice injected with ROME-overexpressing TC-71 cells (n = 11) had a higher total mass of metastatic nodules than did controls (n = 10). C, In a tail vein metastasis model, mice injected with ROME-KO TC-71 cells (n = 11) had a lower total mass of metastases than controls injected with WT TC71 cells (n = 11). Statistical significance was determined via an unpaired t test (one-tailed) for B and C. D, Diagram of the orthotopic Ewing sarcoma leg amputation experimental timeline. E, Representative gross images of lungs from mice injected with TC-71 cells overexpressing ROME or with EV (left) with quantification (middle). Representative images of H&E staining are shown on the right confirming metastatic nodules in the lungs of SCID mice. Statistical significance was calculated by the Fisher exact test (one-sided). F, TC-71 ROME-KO cells displayed significantly reduced primary tumor recurrence [n = 10 per group, log-rank (Mantel–Cox) test]. G, ROME is expressed throughout many different tumor types (CNS, central nervous system; HEPAC, hepatocellular carcinoma and cholangioma; KICH, kidney chromophobe and other renal carcinoma; KIPCC, papillary cell renal carcinoma; OV, ovarian cystadenocarcinoma; PAAD, pancreatic ductal adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; SCC/BLCA, squamous cell or bladder carcinoma; TGCT SEM, testicular germ cell tumor, seminoma). H, Kaplan–Meier curves of patient survival stratified by high (red line) and low (black line) ROME expression (from the Kaplan–Meier plotter database). [A and D, Created in BioRender. Lab, S. (2026) https://BioRender.com/atgnfw0.]
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 6 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Supplementary data for single cell RNA sequencing experiment
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 6 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Supplementary data for single cell RNA sequencing experiment